Emmaus Life Sciences, Inc. (EMMA-OTCQX)

Emmaus Life Sciences, Inc.
21250 Hawthorne Blvd.
Suite 800
Torrance, CA 90503
Phone: (310) 214-0065
https://www.emmausmedical.com/

Emmaus Life Sciences, Inc. (“Emmaus” or “the Company”) is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). Emmaus’ lead commercial product is Endari® (L-glutamine oral powder), an oral treatment indicated to reduce acute complications of SCD in adult and pediatric patients five years or older. Endari® is approved for marketing in the United States, Israel, Bahrain, Kuwait, Qatar, and the United Arab Emirates, and is available on a named patient or early access basis in France, The Netherlands, and the Kingdom of Saudi Arabia. As well, in July 2023, the Company announced that it had received marketing authorization from the Oman Ministry of Health for the commercial distribution. Emmaus is further aggressively seeking marketing approval in geographic regions that account for a significant share of the world’s SCD cases. Endari®’s growth continues to be driven by the effective use of its in-house sales force and its recently launched direct-to-consumer programs, including an innovative full-service telehealth solution that provides online access to Endari®. Emmaus is also involved in assessing L-glutamine to treat diverticulosis, currently in a pilot trial, as well as pre-clinical programs for oncology and regenerative medicine with other compounds. The Company believes its Endari® commercial activities and pipeline of new products provide a sustainable business model, which could result in multiple future revenue sources.

* The Corporate Snapshot was last updated on September 8, 2023.